VP1-2025: Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Final overall survival (OS) from the phase III TROPION-Breast01 trial

Publication | Closed Access

DOI

Citations

References

2025

Year

Barbara Pistilli, Komal Jhaveri, S-A. Im, Sònia Pernas, Michelino De Laurentiis, Shuhua Wang, Giuliano Santos Borges, David W. Cescon, Masaya Hattori, Yen‐Shen Lu,

Annals of Oncology